Drug intelligence / Profile preview

AD2C-Oncology

Development stage: Preclinical
Lead developer: Acepodia
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AD2C-Oncology appears to be based on Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) platform. This technology enables seamless integration of various linker-payload types through a site-selective conjugation process, ensuring high conjugation efficiency while preserving antibody binding capacity. The platform offers flexibility in adjusting the Drug-to-Antibody Ratio (DAR) to align with specific treatment objectives. Its sophisticated dual-payload design effectively addresses tumor heterogeneity often encountered in traditional mono-payload Antibody-Drug Conjugate (ADC) products. Additionally, AD2C can incorporate validated linker-payloads without requiring complex antibody engineering, making it an excellent platform for ADC drug discovery.

Other names: Antibody-Dual-Drugs Conjugation

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on AD2C-Oncology.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD2C-Oncology.

Explore the full profile